Moderna : 2021 guidance adjusted upwards – Growth prospects reiterated
>First quarterly profit for the group - Moderna yesterday evening reported its Q1 2021 results, historically its first quarter in the black. While the top line came in a shade below expectations at $ 1.93bn (vs consensus at $ 2bn), profitability was higher than expected with net profit of $ 1.2bn (vs $ 832m expected). This outperformance was partly due to lower-than- expected COGS (11% of sales vs 23% expected) as a result of the recognition of part of the storage cos...Moderna is creating a new generation of medicines based on messenger RNA to improve the lives of patients. The company uses its platform to identify and develop new mRNA medicines. When the company identifies a combination of platform technologies or programs across mRNA technologies, delivery technologies, and manufacturing processes that can enable shared product features across multiple potential mRNA medicines, it groups those programs as a modality. The company has created six modalities including prohylactic vaccines; cancer vaccines; intratumoral immuno-oncology; localized regenerative therapeuctics; systemic secreted therapeutics; and systemic intracellular therapeutics.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.